Elin Svensson
Elin Svensson
Uppsala University, Radboudumc
Verified email at radboudumc.nl - Homepage
Title
Cited by
Cited by
Year
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
EM Svensson, S Murray, MO Karlsson, KE Dooley
Journal of Antimicrobial Chemotherapy 70 (4), 1106-1114, 2015
912015
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis
EM Svensson, F Aweeka, JG Park, F Marzan, KE Dooley, MO Karlsson
Antimicrobial agents and chemotherapy 57 (6), 2780-2787, 2013
872013
The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis
EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ...
Clinical Infectious Diseases 67 (1), 34-41, 2018
672018
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection
EM Svensson, KE Dooley, MO Karlsson
Antimicrobial agents and chemotherapy 58 (11), 6406-6412, 2014
552014
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria
MM Ruth, JJN Sangen, K Remmers, LJ Pennings, E Svensson, ...
Journal of Antimicrobial Chemotherapy 74 (4), 935-943, 2019
432019
Greater early bactericidal activity at higher rifampicin doses revealed by modeling and clinical trial simulations
RJ Svensson, EM Svensson, RE Aarnoutse, AH Diacon, R Dawson, ...
The Journal of infectious diseases 218 (6), 991-999, 2018
382018
Population pharmacokinetics of Bedaquiline and metabolite M2 in patients with drug‐resistant tuberculosis: the effect of time‐varying weight and albumin
EM Svensson, AG Dosne, MO Karlsson
CPT: pharmacometrics & systems pharmacology 5 (12), 682-691, 2016
352016
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis
MJE Brill, EM Svensson, M Pandie, G Maartens, MO Karlsson
International journal of antimicrobial agents 49 (2), 212-217, 2017
332017
Modelling of mycobacterial load reveals bedaquiline’s exposure–response relationship in patients with drug-resistant TB
EM Svensson, MO Karlsson
Journal of Antimicrobial Chemotherapy 72 (12), 3398-3405, 2017
302017
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics
E Svensson, JS van der Walt, KI Barnes, K Cohen, T Kredo, A Huitema, ...
British journal of clinical pharmacology 74 (3), 465-476, 2012
252012
Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children
AJ Garcia-Prats, EM Svensson, ED Weld, HS Schaaf, AC Hesseling
The International Journal of Tuberculosis and Lung Disease 22 (5), S15-S23, 2018
212018
Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy
EM Svensson, G Yngman, P Denti, H McIlleron, MC Kjellsson, ...
Clinical pharmacokinetics 57 (5), 591-599, 2018
212018
Pharmacokinetic interactions for drugs with a long half-life—evidence for the need of model-based analysis
EM Svensson, C Acharya, B Clauson, KE Dooley, MO Karlsson
The AAPS journal 18 (1), 171-179, 2016
202016
Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis
AA Abulfathi, EH Decloedt, EM Svensson, AH Diacon, P Donald, H Reuter
Clinical pharmacokinetics 58 (9), 1103-1129, 2019
192019
Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials
EM Svensson, S Dian, L Te Brake, AR Ganiem, V Yunivita, ...
Clinical Infectious Diseases 71 (8), 1817-1823, 2020
182020
Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis
G Maartens, MJE Brill, M Pandie, EM Svensson
The International Journal of Tuberculosis and Lung Disease 22 (1), 26-29, 2018
162018
Personalized tuberculosis treatment through model-informed dosing of rifampicin
SW van Beek, R Ter Heine, RJ Keizer, C Magis-Escurra, RE Aarnoutse, ...
Clinical pharmacokinetics 58 (6), 815-826, 2019
152019
Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children
EM Svensson, J du Bois, R Kitshoff, VR de Jager, L Wiesner, J Norman, ...
British journal of clinical pharmacology 84 (10), 2384-2392, 2018
152018
Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs
S Hennig, EM Svensson, R Niebecker, PB Fourie, MH Weiner, S Bonora, ...
Journal of Antimicrobial Chemotherapy 71 (5), 1330-1340, 2016
132016
Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
MM Ruth, VACM Koeken, LJ Pennings, EM Svensson, HFL Wertheim, ...
Journal of Antimicrobial Chemotherapy 75 (3), 609-617, 2020
122020
The system can't perform the operation now. Try again later.
Articles 1–20